Beckman Coulter receives BARDA funding to validate Monocyte Distribution Width in the rapid detection of Multisystem Inflammatory Syndrome , a severe COVID-19 complication in Children

Beckman Coulter, a global clinical diagnostics leader, today announced that it was awarded funding by the Biomedical Advanced Research and Development Authority ( BARDA ) part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for a multi-center clinical trial to validate the ability of its Monocyte Distribution Width (MDW) hematology biomarker to aid in the rapid detection of Multisystem Inflammatory Syndrome in Children (MIS-C). Recently defined by the Centers for Disease Control and Prevention (CDC), MIS-C is a rare but severe complication seen in children following SARS-CoV-2 infection.

Beckman Coulter receives BARDA funding to validate Monocyte Distribution Width in the rapid detection of Multisystem Inflammatory Syndrome (MIS-C), a severe COVID-19 complication in Children

The BARDA award will help fund a collaborative effort between Beckman Coulter and academic partners at Massachusetts General Hospital (MGH), Johns Hopkins University School of Medicine and the University of Florida to validate the effectiveness of the biomarker to detect MIS-C with a large, multi-center clinical trial to support regulatory submissions. Preliminary results from a study initiated at MGH earlier this year revealed that MDW has the potential to aid in the rapid detection of MIS-C. An abnormal MDW could potentially aid in triaging patients for care, starting treatment early and determining patient disposition.

"Primary care doctors and emergency department physicians need a rapid, reliable diagnostic test for MIS-C to accurately identify children early in the illness," said Lael Yonker , M.D., pediatric pulmonologist at MGH, assistant professor at Harvard Medical School and one of the lead researchers on the study. "Fevers are very common in kids, but most are caused by self-limiting infections or they resolve with antibiotics. MIS-C also presents with fever, but it can progress to a severe, life-threatening illness."

Initially reported as hyperinflammatory shock and " Kawasaki -like" illness, MIS-C has been observed to have overlapping features with toxic shock syndrome, atypical Kawasaki disease, macrophage activation syndrome, and cardiogenic and septic shock. Although most MIS-C patients survive with adequate intensive care, deaths have been reported 1,2 . The long-term consequences of MIS-C are currently unknown.

"Identifying MIS-C is challenging because the primary symptom is one of the most common symptoms prompting pediatric evaluation in children of all ages," said Shamiram R. Feinglass , M.D., M.P.H., chief medical officer, Beckman Coulter. "Given the community spread of COVID-19, empowering clinicians with a tool to aid in the early detection of MIS-C is critical because, undetected, MIS-C can result in the rapid onset of hypotensive shock, cardiac aneurysm or ventricular failure. The MDW biomarker is unique because it is available as part of a routine complete blood cell count. Having this specific data so early in the encounter enables physicians to act fast when every moment matters."

Beckman Coulter's MDW biomarker is a measure of increased morphological variability of monocytes, which can biologically indicate the presence of a systemic infection. The quantitative analysis of MDW has received regulatory clearances as an aid for early detection in adult patients with or developing sepsis in emergency departments. Considered with other signs and symptoms, the value of MDW helps differentiate sepsis from non-septic presentations, including non-infectious, systemic inflammatory response.

The research to explore MDW's utility in aiding in the rapid detection of MIS-C is part of BARDA's Rapidly Deployable Capabilities program to identify and pilot near-term innovative solutions for COVID-19. For more information on Beckman Coulter's MDW biomarker, visit www.BeckmanCoulter.com/sepsis . For more information on BARDA's rapidly-expanding COVID-19 medical countermeasure portfolio, visit BARDA's COVID-19 Portfolio .

About Beckman Coulter

Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology and the passion and creativity of our teams to enhance the diagnostic laboratory's role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. An operating company of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter is headquartered in Brea, Calif. , and has more than 11,000 global associates working diligently to make the world a healthier place.

References:

1 Cheung, E. W. et al. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City . JAMA 324, 294-296, doi:10.1001/jama.2020.10374 (2020).

2 Feldstein, L. R. et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med 383, 334-346, doi:10.1056/NEJMoa2021680 (2020).

© 2020 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Beckman Coulter logo. (PRNewsfoto/Beckman Coulter)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/beckman-coulter-receives-barda-funding-to-validate-monocyte-distribution-width-in-the-rapid-detection-of-multisystem-inflammatory-syndrome-mis-c-a-severe-covid-19-complication-in-children-301152999.html

SOURCE Beckman Coulter Diagnostics

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

  • Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with Medtronic, plc (NYSE: MDT) in December 2023
  • Orchestra BioMed and Terumo remain actively engaged to update operational plans and financial arrangements for Virtue ® Sirolimus AngioInfusion TM Balloon ("SAB") development and commercialization for treatment of coronary and peripheral artery disease
  • Expected runway of cash and cash equivalents and marketable securities, including certain potential future proceeds sufficient into 2H 2026, beyond anticipated BACKBEAT top-line results readout

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update.

"2023 was a year of strong momentum for Orchestra BioMed as we made significant progress on our cardiovascular pipeline with the achievement of key regulatory milestones and completion of our successful Nasdaq listing," commented David Hochman, chairman, chief executive officer and founder of Orchestra BioMed. "In December, we initiated the BACKBEAT global pivotal study evaluating our lead program, AVIM therapy, in hypertensive pacemaker patients working alongside our strategic partner Medtronic, the global market leader in cardiac pacing therapies. We see a substantial market opportunity for AVIM therapy in this patient population, as well as in other high-risk hypertension populations."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

The Evolutâ„¢ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

2023 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company")  announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 21, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×